It was a pleasure to meet Dr Ahmet Sezer to discuss the clinical development of cemiplimab as a potential treatment for non-small cell lung cancer and key safety and efficacy findings from the EMPOWER- Lung 1 study. The late-breaking abstract, ‘EMPOWER-Lung 1: Phase 3 first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%’ (LBA52) was presented at the Virtual 2020 ESMO Congress, 19–21 September 2020.
Questions
- What have been the challenges of using immune checkpoint inhibitor monotherapies in the first-line treatment of non-small cell lung cancer (NSCLC)? (0:05)
- What were the aims, design and eligibility criteria of the EMPOWER-Lung 1 study? (1:43)
- What were the efficacy and safety findings of the study? (2:59)
- What will be the impact of these findings on clinical practice? (3:56)
- What will be the next step in the clinical development of cemiplimab? (4:20)
Speaker Disclosures: Dr Ahmet Sezer has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. The EMPOWER-Lung 1 study was funded by Regeneron Pharmaceuticals, Inc. and Sanofi.
Filmed in coverage of the Virtual 2020 ESMO Congress.
